SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webc ...

Company Overview - Labrador Gold Corp. is a Canadian mineral exploration company focused on acquiring and exploring gold projects in Eastern Canada [4] - The company currently has approximately CAD $18.1 million in cash [4] - Labrador Gold has 170,009,979 common shares issued and outstanding, trading on the TSX Venture Exchange under the symbol LAB [7] Leadership Appointment - Ryan Weston has been appointed as Vice President Exploration, bringing over 20 years of global experience in base and precious metals exploration [2] - Weston previously played key roles in the successful sales of Carlisle Goldfields for CAD $28 million in 2016 and Noront Resources for CAD $686 million in 2022 [2] - He has served as Vice President Exploration at Wyloo, leading initiatives in Ontario's Ring of Fire region [2] Strategic Vision - Weston expressed confidence in Labrador Gold's strong position to pursue major gold discoveries without the immediate need for additional financing [3] - The company aims to leverage Weston's extensive experience in leading technical teams for new gold projects [3] Exploration Projects - The Hopedale property covers a significant portion of the Florence Lake greenstone belt, which is underexplored compared to similar global belts [5] - Labrador Gold has identified gold anomalies over a 3-kilometer section of the northern part of the Florence Lake greenstone belt, with five gold occurrences discovered [5] - The Borden Lake project near Chapleau, Ontario, has shown promising results with up to 48 gold grains identified in till samples [6]

Core Viewpoint - Standard BioTools Inc. announced the strategic sale of SomaLogic to Illumina for a total of up to $425 million, which includes an upfront payment of $350 million and potential milestone payments of up to $75 million, simplifying its operating structure and enabling adjusted EBITDA break-even [1][2][5]. Financial Details - The transaction includes an upfront cash payment of $350 million at closing and up to $75 million in near-term milestone payments based on specified revenue targets for fiscal years 2025 and 2026 [5][6]. - Standard BioTools will retain a 2% royalty on net revenues from SOMAmer-based NGS library preparation kits for 10 years post-transaction [6]. Strategic Implications - The sale is expected to provide Standard BioTools with at least $550 million in cash at closing, allowing for future inorganic growth strategies and long-term value creation [1][2]. - The transaction is part of a disciplined M&A strategy aimed at acquiring high-potential assets with validated science and a clear commercialization path [3][4]. Operational Impact - The sale significantly simplifies the operational and organizational structure of Standard BioTools, facilitating a path to achieve adjusted EBITDA break-even, which is a key priority for the company [2][4]. - The management team believes that disciplined operations and focused execution can unlock meaningful value in the life sciences sector [2]. Regulatory and Advisory Aspects - The transaction is subject to regulatory approvals and is expected to close in the first half of 2026 [7]. - Centerview Partners LLC is serving as the financial advisor to Standard BioTools, with additional legal counsel from Freshfields LLP and Richards, Layton & Finger, P.A. [8].

TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | OTCQB: NKOSF | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce that a field crew has mobilized to the Hopedale gold project in Labrador and that work has begun on the 2025 exploration program. The district scale Hopedale property covers a 43km strike length of the Archean-age Florence Lake greenstone belt which has characteristics typical of greenstone belts around the world but has been underexplored by comparison. E ...

Core Insights - Standard BioTools Inc. has launched its inaugural Proteomics Roundtable Series to discuss advancements in the field of proteomics and its implications for healthcare [1] - The first session will focus on high-plex, high-quality proteomics, featuring insights from researchers involved in the EPIC cancer study [2] - Future sessions will cover various topics, including comparative metrics for proteomic platforms, deployment in biobanks, and the role of proteomics in accelerating drug development [3][4][5] Company Overview - Standard BioTools Inc. is a leading provider of next-generation technologies aimed at enhancing biomedical research and drug development [7] - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide reliable insights into health and disease [7] - Standard BioTools collaborates with academic, government, and clinical laboratories globally, focusing on critical areas in translational and clinical research [9]

TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | OTCQB: NKOSF | FNR: 2N6) (“LabGold” or the “Company”) announces the resignation of Kai Hoffmann as a director of the Company. Mr. Hoffmann has been an integral part of the Board of Directors since his appointment in 2019. "On behalf of the members of the Board and management team of LabGold, I would like to thank Kai for his valued contributions and commitment to the success of the Company over the past six years," said Roger Moss, ...

Core Viewpoint - Standard BioTools Inc. reported its financial results for Q1 2025, highlighting its operational performance, market trends, and strategic initiatives for the year ahead [3]. Financial Performance - The company released its financial results for the quarter ended March 31, 2025, during the earnings conference call [3]. - The call included discussions on the company's financial outlook for 2025 and future projections [4]. Strategic Initiatives - The management provided updates on strategic initiatives and the expected synergies from the combined operations with SomaLogic [4]. - The company emphasized its focus on market trends and opportunities that may impact its business [4].

Group 1 - Standard BioTools reported a quarterly loss of $0.04 per share, which is an improvement from a loss of $0.23 per share a year ago, aligning with the Zacks Consensus Estimate [1] - The company posted revenues of $40.8 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.73%, but down from $45.54 million year-over-year [2] - Standard BioTools shares have declined approximately 34.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] Group 2 - The earnings outlook for Standard BioTools is mixed, with current consensus EPS estimates at -$0.05 for the coming quarter and -$0.16 for the current fiscal year, with revenues expected at $38.9 million and $169.2 million respectively [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Standard BioTools (LAB) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants ​John Graziano - Vice President of Investor RelationsMichael Egholm - President & CEOAlex Kim - CFOPaul Knight - Managing Director Conference Call Participants Kyle Boucher - AnalystMatthew Stanton - Analyst Operator Please note this event is being recorded. I would now like to turn the conference over to John Graziano, Vice President of Investor Relations. Please go ahead. ​John Graziano Thank you, operator, and goo ...

PART I [Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20%28unaudited%29) The unaudited condensed consolidated financial statements for Q1 2025 show total revenues of **$40.8 million**, a net loss of **$26.0 million**, and a re-segmentation into a single operating segment [Note 2. Business Combinations](index=11&type=section&id=Note%202.%20Business%20Combinations) Purchase accounting for the SomaLogic merger was finalized with no adjustments, while the Sengenics acquisition saw a **$0.3 million** increase in goodwill and deferred tax liability - The purchase accounting for the SomaLogic merger was finalized as of December 31, 2024, with no measurement period adjustments recorded after the closing date, resulting in a bargain purchase gain of **$25.2 million**[39](index=39&type=chunk) - For the Sengenics acquisition, a measurement period adjustment was recorded in Q1 2025, increasing goodwill and deferred tax liability by **$0.3 million** due to the finalization of tax estimates[40](index=40&type=chunk) [Note 3. Revenue and Geographic Area](index=12&type=section&id=Note%203.%20Revenue%20and%20Geographic%20Area) Total revenue for Q1 2025 decreased to **$40.8 million** due to lower consumables and lab services, with Americas remaining the largest region despite a decline Revenue by Type (Q1 2025 vs Q1 2024) | Revenue Type | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Instruments | $7,778 | $6,285 | | Consumables | $14,454 | $17,307 | | Lab services | $12,106 | $14,862 | | Field services | $5,501 | $6,165 | | **Total Revenue** | **$40,795** | **$45,540** | Revenue by Geographic Area (Q1 2025 vs Q1 2024) | Geographic Area | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Americas | $18,974 | $24,664 | | Europe, Middle East and Africa | $12,606 | $12,515 | | Asia-Pacific | $9,215 | $8,361 | | **Total Revenue** | **$40,795** | **$45,540** | - The company assumed a multi-year agreement with Illumina, including **$124.5 million** of minimum guaranteed royalties and a material right for Illumina to purchase SOMAmer reagents below standalone selling price, with the total transaction price estimated at **$158.4 million** to be recognized over an **8-year period** from 2025 to 2032[43](index=43&type=chunk)[44](index=44&type=chunk)[45](index=45&type=chunk) [Note 4. Goodwill and Acquired Intangible Assets, net](index=14&type=section&id=Note%204.%20Goodwill%20and%20Acquired%20Intangible%20Assets%2C%20net) Goodwill increased slightly to **$111.7 million** due to adjustments, with no impairment recorded after re-assessing reporting units to a single segment - Due to the change in reportable segments in Q1 2025, the company re-assessed its reporting units for goodwill impairment testing, consolidating from two units to one, and **no goodwill impairment** was recorded[52](index=52&type=chunk) Changes in Goodwill (Q1 2025) | Description | Amount (in thousands) | | :--- | :--- | | Balance as of December 31, 2024 | $111,297 | | Measurement period adjustment (Sengenics) | $336 | | Foreign currency translation | $86 | | **Balance as of March 31, 2025** | **$111,719** | [Note 6. Commitments and Contingencies](index=18&type=section&id=Note%206.%20Commitments%20and%20Contingencies) The company has **$8.9 million** in purchase commitments and faces ongoing stockholder litigation related to the SomaLogic merger, with an uncertain outcome - The company has minimum purchase commitments with Integrated DNA Technologies, Inc. (IDT) of **$2.3 million** annually for three years, and with LGC Genomics (LGC) of **$1.0 million** annually for two years[63](index=63&type=chunk)[64](index=64&type=chunk) - The company is facing ongoing stockholder litigation related to the SomaLogic merger, alleging breach of fiduciary duty, with a motion to dismiss pending and oral arguments scheduled for July 7, 2025, and the **outcome is uncertain**[70](index=70&type=chunk) Condensed Consolidated Statements of Operations (Q1 2025 vs Q1 2024) | Financial Metric | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Total Revenue | $40,795 | $45,540 | | Gross Profit | $19,741 | $24,188 | | Loss from Operations | $(32,970) | $(60,182) | | Net Loss | $(26,033) | $(32,157) | | Net Loss per Share (basic and diluted) | $(0.07) | $(0.27) | Condensed Consolidated Balance Sheets (As of March 31, 2025) | Balance Sheet Item | March 31, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $150,880 | $166,728 | | Total Current Assets | $344,019 | $375,880 | | Total Assets | $579,597 | $612,344 | | Total Current Liabilities | $56,236 | $65,894 | | Total Liabilities | $125,002 | $140,622 | | Total Stockholders' Equity | $454,595 | $471,722 | - Effective Q1 2025, following the full integration of SomaLogic, the company changed its management structure and now operates as a **single, consolidated multi-omics company**, moving away from its previous two-segment structure (proteomics and genomics)[32](index=32&type=chunk)[99](index=99&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses a **10% revenue decrease** to **$40.8 million** in Q1 2025, offset by a **38% reduction in operating expenses**, improving net loss to **$26.0 million**, with **$258.1 million** in liquidity [Results of Operations](index=32&type=section&id=Results%20of%20Operations) Q1 2025 total revenue decreased **10%** to **$40.8 million** due to lower services and consumables, while operating expenses fell **38%** to **$52.7 million** from reduced transaction costs and restructuring Revenue Change by Type (Q1 2025 vs Q1 2024) | Revenue Type | Q1 2025 (in thousands) | Q1 2024 (in thousands) | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Instruments | $7,778 | $6,285 | $1,493 | 24% | | Consumables | $14,454 | $17,307 | $(2,853) | (16)% | | Lab services | $12,106 | $14,862 | $(2,756) | (19)% | | Field services | $5,501 | $6,165 | $(664) | (11)% | | **Total Revenue** | **$40,795** | **$45,540** | **$(4,745)** | **(10)%** | Operating Expense Change (Q1 2025 vs Q1 2024) | Expense Category | Q1 2025 (in thousands) | Q1 2024 (in thousands) | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $11,328 | $15,980 | $(4,652) | (29)% | | Selling, general and administrative | $38,707 | $46,943 | $(8,236) | (18)% | | Restructuring and related charges | $1,552 | $4,284 | $(2,732) | (64)% | | Transaction and integration expenses | $1,124 | $17,163 | $(16,039) | (93)% | | **Total Operating Expenses** | **$52,711** | **$84,370** | **$(31,659)** | **(38)%** | - The decrease in operating expenses was primarily driven by **reductions in headcount** from 2024 restructuring activities, reduced investment in certain R&D projects, and a **significant drop in one-time legal, advisory, and integration costs** associated with the SomaLogic merger in the prior-year period[133](index=133&type=chunk)[134](index=134&type=chunk)[136](index=136&type=chunk) [Liquidity and Capital Resources](index=34&type=section&id=Liquidity%20and%20Capital%20Resources) The company ended Q1 2025 with **$258.1 million** in liquidity, sufficient for **12 months**, and significantly improved operating cash flow to **$30.3 million** used, with no traditional debt - The company believes its existing liquidity of **$258.1 million** (cash, cash equivalents, and short-term investments) is sufficient to support operations for **at least the next 12 months**[146](index=146&type=chunk)[147](index=147&type=chunk) Cash Flow Summary (Q1 2025 vs Q1 2024) | Cash Flow Activity | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | $(30,283) | $(62,476) | | Net cash provided by investing activities | $14,625 | $318,075 | | Net cash used in financing activities | $(46) | $(19,733) | - Net cash used in operating activities decreased by **$32.2 million** YoY due to lower operating expenses following the completion of 2024 restructuring activities[154](index=154&type=chunk) - As of March 31, 2025, the company has **fully repaid all traditional debt obligations** and no longer maintains access to credit facilities[148](index=148&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks from interest rates, foreign currency, inflation, and capital markets, though foreign currency impact has not been material - Primary market risks include **interest rate risk** on cash and investments, **foreign currency risk** from international operations, **inflation risk** on operating costs, and **capital market risk** affecting the ability to raise funds[164](index=164&type=chunk) - The company does not currently hedge its foreign currency exposure, and changes in currency values have **not had a material impact** on recent financial results[166](index=166&type=chunk) [Controls and Procedures](index=38&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of March 31, 2025, despite implementing a new ERP system that changed internal controls over financial reporting - The CEO and CFO concluded that as of March 31, 2025, the company's disclosure controls and procedures were **effective at the reasonable assurance level**[170](index=170&type=chunk) - A **new enterprise resource planning (ERP) system** was implemented in Q1 2025, representing a **change in internal control over financial reporting**, and management is taking steps to test and validate the new controls[171](index=171&type=chunk) PART II [Legal Proceedings](index=41&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to Note 6 for details on legal proceedings, primarily ongoing stockholder litigation related to the SomaLogic merger - For detailed information on legal proceedings, the report refers to **Note 6** of the financial statements[175](index=175&type=chunk) [Risk Factors](index=41&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors were reported, with readers directed to the Annual Report on Form 10-K for a full discussion - The company refers to the risk factors discussed in its Annual Report on Form 10-K, indicating **no new material risks** have emerged during the quarter[176](index=176&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=41&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered equity sales occurred, and no shares were repurchased under the **$50.0 million** program during Q1 2025, with **$40.5 million** previously utilized - The company **did not repurchase any shares** of its common stock during the three months ended March 31, 2025, under its authorized **$50.0 million** share repurchase program[178](index=178&type=chunk) [Other Information](index=41&type=section&id=Item%205.%20Other%20Information) No officers or directors adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during Q1 2025 - **No officers or directors** adopted, modified, or terminated any **Rule 10b5-1 trading arrangements** during Q1 2025[181](index=181&type=chunk) [Exhibits](index=42&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including CEO and CFO certifications and Inline XBRL data files - The Exhibit List includes **CEO and CFO certifications** pursuant to **Sarbanes-Oxley Sections 302 and 906**, as well as **Inline XBRL documents**[184](index=184&type=chunk)